Thyroid hormones associate with risk of incident chronic kidney disease and rapid decline in renal function: a prospective investigation

Xiaolin Huang1,2†, Lin Ding1,2†, Kui Peng1,2, Lin Lin1,2, Tiange Wang1,2, Zhiyun Zhao1,2, Yu Xu1,2, Jieli Lu1,2, Yuhong Chen1,2, Weiqing Wang1,2, Yufang Bi1,2, Guang Ning1,2 and Min Xu1,2*

Abstract

Background: Thyroid hormones have been associated with renal dysfunction in cross-sectional studies. However, prospective studies exploring the effect of thyroid hormones on renal function decline were sparse and got contradictory results. We aimed to prospectively explore the associations of thyroid hormones with incident chronic kidney disease (CKD) and rapid decline in estimated glomerular filtration rate (eGFR) in Chinese adults.

Methods: The participants were from a community-based cohort including 2103 individuals aged 40 years or above without CKD at baseline. Thyroid-stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxin (FT4) were measured by radioimmunoassay at baseline. Serum creatinine, urinary creatinine and albumin were measured at baseline and follow-up. CKD was defined as eGFR <60 ml/min/1.73 m² or urinary albumin-to-creatinine ratio ≥30 mg/g. Rapid eGFR decline was defined as an annual eGFR decline >3 ml/min/1.73 m².

Results: During 4 years of follow-up, 198 participants developed CKD and 165 experienced rapid eGFR decline. Compared to tertile 1, tertile 3 of FT4 levels were associated with 1.88-folds (95% confidence interval [CI], 1.27–2.77) increased risk of incident CKD; and 1.64-folds (95% CI, 1.07–2.50) increased risk of rapid eGFR decline (both P for trend ≤0.02), after adjustment for confounders. Each 1-pmol/l of FT4 was associated with 12% increased risk of incident CKD and 10% of rapid eGFR decline. Among the incident CKD individuals, FT4 was significantly associated with higher risk of concurrent complications and further outcomes of CKD. We did not find associations of FT3 or TSH with CKD or rapid eGFR decline.

Conclusions: Higher FT4, but not TSH and FT3, was associated with increased risk of incident CKD and rapid eGFR decline in middle-aged and elderly Chinese.

Keywords: Thyroid hormones, Chronic kidney disease, Renal function, Glomerular filtration rate
help extensively understand the pathogenesis of CKD and develop new prevention strategies for CKD.

Thyroid hormones, which are crucial for regulation of human body’s physiological actions, were found influencing GFR, renal blood flow, tubular secretory and reabsorptive processes as well [10–12]. Previous studies reported that overt and subclinical hypothyroidism were associated with higher levels of serum creatinine, reduced eGFR and increased risk of CKD [13–16]. Hyperthyroidism, however, can also lead to or accelerate the development of CKD [17]. In fact, most of the evidence was derived from cross-sectional studies [18, 19]. Prospective studies exploring the effect of thyroid hormones on renal function decline were sparse and got contradictory results [20, 21]. One study showed that normal-to-high levels of thyroid-stimulating hormone (TSH) and normal-to-low levels of free triiodothyronine (FT3) were associated with an increased risk of incident CKD in euthyroid individuals [20]. While the other reported non-significant association between thyroid dysfunction and changes in renal function among older adults [21].

In the present investigation, we aimed to explore prospectively the associations of thyroid hormones with risk of incident CKD and rapid eGFR decline; in addition, we examined the associations with predicted risks for concurrent complications and further outcomes of CKD, among the incident CKD participants.

Methods

Study population and design

All participants of the present study were recruited from Songnan Community, Baoshan district, Shanghai, in two stages as reported previously [22, 23]. In stage 1, 10,185 residents aged 40 years old or above were enrolled to the screening examination in June and July 2008. According to different levels of fasting plasma glucose (FPG), all participants were categorized into three groups: normal glucose regulation, impaired glucose regulation and diabetes. In stage 2, from June to August 2009, 4012 participants were randomly selected from the three groups on a ratio of 1.44 (normal glucose regulation) to 1.2 (impaired glucose regulation) to 1.0 (diabetes) because subjects with lower glucose levels were expected to have a lower participation rate than those with higher glucose levels, for a more comprehensive survey.

Among the 4012 participants, 3455 participants had both blood and urine samples. For the present analysis, participants were excluded sequentially as follows, with a history of thyroid dysfunction (history of overt hyperthyroidism, hypothyroidism or thyroiditis, taking or had previously taken thyroxine or antithyroid drugs, n = 12), currently taking medications which affecting thyroid function (n = 5), with a history of thyroideectomy (n = 2), with inadequate sample for thyroid measurements (n = 42), with missing data on serum creatinine, urinary creatinine and albumin (n = 3), and with eGFR <60 ml/min/1.73 m² (n = 205) or urinary albumin-to-creatinine ratio (ACR) ≥30 mg/g (n = 309). After exclusion, 2877 participants were eligible. From March to June 2013, all the 2877 participants were invited to have a follow-up study. 26 participants died during the follow-up. Eventually, 2103 participants responded and participated in the follow-up study (details on Fig. 1).

Written informed consent was obtained by each participant and the study protocol was approved by the Institutional Review Board of Rui-Jin Hospital.

Data collection

A questionnaire survey and anthropometric measurements were conducted both at the baseline and follow-up visit. Sociodemographics, lifestyle factors and medical history were collected by trained physicians with a standard questionnaire via face-to-face interview. Current drinkers and smokers were defined as those who consumed alcohol at least once a week, and those who smoked a cigarette per day or seven cigarettes per week in the past 6 months, respectively. The information on body weight and height was measured with participants wearing light weight clothing and no shoes. Body mass index (BMI) was calculated as weight in kilograms divided into squared height in meters. Waist circumference was measured at umbilical level in a standing position. After at least 5 min rest, blood pressure was measured three times with 1-min interval using an automated electronic device (OMRON Model HEM-752 FUZZY, Omron Company, Dalian, China), at the non-dominant arm in a seated position. The average of the three readings was used for analysis.

Biochemical measurements

After an at least 10 h overnight fast, the venous sample was collected and a 75-g oral glucose tolerance test (OGTT) was performed for each participant both at the baseline and follow-up visit. Levels of serum triglyceride, high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), total cholesterol (TC), and serum creatinine (Cr) were measured by an autoanalyser (ADVIA-1650 Chemistry System, Bayer Corporation, Germany). FPG and OGTT 2-h plasma glucose were measured with using the glucose oxidase method on an autoanalysers (ADVIA-1650 Chemistry System, Bayer Corporation, Germany), and hemoglobin A1c (HbA1c) was determined by high-performance liquid chromatography (BIO-RAD D-10, USA). eGFR was evaluated using the 2009 chronic kidney disease epidemiology collaboration (CKD-EPI) equation [24] according
to the recommendation in the 2012 kidney disease: improving global outcomes (KDIGO) clinical practice guideline for the evaluation and management of CKD [1]:
(1) Females: Cr ≤ 0.7 mg/dl, eGFR = 144 × (Cr/0.7)^{-0.329} × (0.993)^{age}; Cr > 0.7 mg/dl, eGFR = 144 × (Cr/0.7)^{-1.209} × (0.993)^{age}. (2) Males: Cr ≤ 0.9 mg/dl, eGFR = 141 × (Cr/0.9)^{-0.411} × (0.993)^{age}; Cr > 0.9 mg/dl, eGFR = 141 × (Cr/0.9)^{-1.209} × (0.993)^{age}.

A first-voided, early-morning spot urine was collected to measure the urinary albumin and creatinine using rate nephelometry (Beckman Coulter, Fullerton, CA) and alkaline nitroxanthic acid method, respectively. Urinary ACR was calculated as milligrams of urinary albumin excretion per gram of urinary creatinine.
Outcomes
In present study, the primary outcome was incident CKD which was defined as the presence of eGFR <60 ml/min/1.73 m² or urinary ACR ≥30 mg/g at the follow-up visit [26]. The secondary outcome was rapid eGFR decline which was defined as an annual decline [(eGFR at follow-up—eGFR at baseline)/follow-up period (years)] in eGFR >3 ml/min/1.73 m² [27].

Furthermore, among the participants who developed CKD, we predicted the risks of concurrent complications and further outcomes of CKD by combining eGFR with albuminuria in the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD [1]. It was classified into four colored risk zones for prognosis: low risk, green; moderately increased risk, yellow; high risk, orange; and very high risk, red.

Statistics analysis
All statistical analyses were performed by using SAS version 9.3 (SAS Institute Inc, Cary, NC, USA). The values of serum TSH, TPOAb, TGAAb, triglyceride, FPG and HbA1c, and urinary ACR were normalized by logarithmic transformation because of skewed distributions. Continuous variables were shown as means ± standard deviations (SDs) for those with normal distribution and were shown as medians (interquartile ranges) for those with skewed distribution. All categorical variables were presented as numbers (proportions). Thyroid function measurements were treated as continuous variables with one-unit increase or categorical variables by tertiles: <13.60, 13.60–14.83 and ≥14.84 pmol/l for serum FT4; <4.43, 4.43–4.83 and ≥4.84 pmol/l for serum FT3; <1.151, 1.151–1.860 and ≥1.861 μIU/ml for serum TSH.

Comparisons of baseline characteristics between non-CKD and incident CKD individuals were performed by using t test for continuous variables and Chi-square test for categorical variables. P values for trend for percent-ages of incident CKD and rapid eGFR decline were tested by using Cochran–Mantel–Haenszel (CMH) method among tertiles of serum FT4.

Multivariable logistic regression analysis was used to evaluate the associations of serum FT4, as well as serum FT3 and TSH, with the development of CKD and rapid eGFR decline. In model 1, age, sex and BMI at baseline were adjusted; in model 2, triglyceride, HDL-c, LDL-c, urinary ACR (for incident CKD only) and eGFR, current smoking and drinking, diabetes and hypertension status, and usage of antidiabetic or antihypertensive drugs at baseline were further adjusted based on model 1; in model 3, serum TPOAb and TGAb levels at baseline were further adjusted based on model 2. Additionally, we used the multinomial logit regression analysis to evaluate the associations of baseline serum FT4 levels with the predicted risks for future outcomes of CKD, among incident CKD individuals.

Significance tests were two-tailed and a P value less than 0.05 was considered to be statistically significant.

Results
Characteristics of the participants at baseline
A total of 2103 participants free of CKD at baseline were included in current analyses. The mean age was 59.3 years old and 39.3% were males. During the 4-year follow-up period, 198 (9.4%) participants developed CKD and 165 (7.8%) experienced rapid eGFR decline. Table 1 shows baseline characteristics of the participants according to incident CKD status. Participants who developed CKD were older, had higher BMI, waist circumference, blood pressure, serum triglyceride, FPG, HbA1c and urinary ACR, and lower level of eGFR (all P values <0.05). 26.3% of those who developed CKD at follow-up were taking antidiabetic drugs and 31.8% were using antihypertensive drugs, significantly higher than that of non-CKD participants (all P values <0.05). In particular, levels of serum FT4, but not FT3 and TSH, were higher among the incident CKD participants than non-CKD ones (P < 0.0001). No significant differences were observed in levels of HDL-c, LDL-c, TC, TPOAb, TGAb, sex distribution, or status of current smoking and drinking at baseline between incident CKD and non-CKD participants.

Association of thyroid hormones with incident CKD
The incidence of CKD gradually increased according to serum FT4 tertiles: 6.7, 8.6 and 12.9% for tertile 1, tertile 2 and tertile 3, respectively. As compared to tertile 1, tertile 3 of FT4 levels was associated with 88% increased risk of developing CKD (95% confidence interval [CI] 1.27–2.77; P for trend = 0.001), after adjustment for the confounding factors (Model 3). The continuous variable
analysis showed similar results. Each 1-pmol/l of FT4 was associated with 12% (95% CI 1.05–1.20) increased risk of incident CKD. We did not find a significant association between serum FT3 or TSH and incident CKD (Table 2).

**Association of thyroid hormones with rapid eGFR decline during follow-up**

During follow-up, the eGFR levels of non-CKD individuals significantly increased, while those of incident CKD participants were decreased (all P values <0.05). In follow-up study, eGFR of non-CKD and incident CKD individuals were 93.0 ± 10.6 and 84.1 ± 18.1 ml/min/1.73 m², respectively. With the increment of serum FT4 tertiles, the percentages of rapid eGFR decline gradually increased (P for trend = 0.0004). Multivariable logistic regressions showed that the odds ratio (OR) for rapid eGFR decline in the highest FT4 tertile versus the lowest tertile was 1.64 (95% CI 1.07–2.50), after adjustment for various confounders. Each 1-pmol/l increase of serum FT4 was associated with 10% increased risk of rapid eGFR decline. We did not find a significant association between serum FT3 or TSH and risk of rapid eGFR decline (Table 3).

**Association of baseline serum FT4 levels with the predicted risks for future outcomes of CKD**

According to the recommendations in the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD [1], among the 198 participants who developed CKD during follow-up, 177 participants were at moderately increased risk of concurrent complications and further outcomes of CKD, 17 and 4 were at high risk and very high risk, respectively.

Table 4 shows associations of baseline serum FT4 levels with the predicted risks for future outcomes of CKD, among incident CKD individuals. After adjusting for a wide range of covariates, each 1-pmol/l increase and each 1-tertile increase of FT4 associated 11% and 30% increased risk for moderately increased risk of concurrent complications and further outcomes of CKD, respectively; and 22% and 161% increased risk for the combined high and very high increased risk of concurrent complications and further outcomes among incident CKD individuals, respectively.

**Discussion**

In this community-based prospective investigation, we found that high levels of serum FT4 significantly associated with renal function decline in middle-aged and elderly Chinese. Major findings in our study were: (1) elevated levels of serum FT4 at baseline associated with increased risk of incident CKD and rapid eGFR decline; (2) serum FT4 positively associated with the increased risk for concurrent complications and further outcomes of CKD; (3) no significant associations of serum FT3, TSH with incident CKD or rapid eGFR decline were found in the present analysis.

In our study, we reported significant associations of FT4 with both incident CKD and rapid eGFR decline in a large general Chinese population, suggesting that when a higher FT4 level was found in clinical practice, a screening for kidney disease is warranted beyond hyperthyroidism treatments and the thyroid function monitoring. Our results were consistent with several previous findings. A prospective study focusing on thyroid function status and renal function in older persons found that overt hypothyroidism provided a protective effect on changes in renal function.

### Table 1 Baseline characteristics of the participants according to incident CKD status

| Characteristics | Non-CKD | Incident CKD | P value |
|-----------------|---------|--------------|---------|
| n, %            | 1905 (90.6) | 198 (9.4) | – |
| Age (years)     | 58.9 ± 8.9 | 63.1 ± 10.1 | <0.0001 |
| Male (n, %)     | 753 (39.5) | 73 (36.9) | 0.47 |
| BMI (kg/m²)     | 24.7 ± 3.4 | 25.5 ± 3.8 | 0.0006 |
| Waist circumference (cm) | 86.3 ± 9.4 | 89.5 ± 9.7 | <0.0001 |
| Current drinker (n, %) | 344 (18.1) | 40 (20.2) | 0.58 |
| Current smoker (n, %) | 382 (20.1) | 39 (19.7) | 0.81 |
| SBP (mmHg)      | 134 ± 24 | 144 ± 27 | <0.0001 |
| DBP (mmHg)      | 78 ± 10 | 81 ± 10 | 0.001 |
| Triglyceride (mmol/l) | 1.40 (0.96–2.02) | 1.48 (1.01–2.41) | 0.02 |
| LDL-C (mmol/l)  | 2.40 ± 0.68 | 2.35 ± 0.68 | 0.30 |
| HDL-C (mmol/l)  | 1.37 ± 0.30 | 1.34 ± 0.31 | 0.31 |
| Total cholesterol (mmol/l) | 5.15 ± 0.96 | 5.11 ± 1.05 | 0.64 |
| FPG (mmol/l)    | 5.1 (4.7–5.8) | 5.6 (5.0–7.0) | <0.0001 |
| HbA1c (%)       | 6.1 (5.7–6.5) | 6.4 (5.9–7.6) | <0.0001 |
| TSH (μIU/ml)    | 1.44 (1.03–2.14) | 1.44 (1.01–2.07) | 0.35 |
| FT3 (pmol/l)    | 4.65 ± 0.55 | 4.72 ± 1.11 | 0.16 |
| FT4 (pmol/l)    | 14.27 ± 1.80 | 14.85 ± 2.36 | <0.0001 |
| TGAb (IU/ml)    | 0.30 (0.17–0.73) | 0.32 (0.18–0.71) | 0.55 |
| TPOAb (IU/ml)   | 1.06 (0.71–2.44) | 0.93 (0.71–1.91) | 0.09 |
| eGFR (ml/min/1.73 m²) | 92.4 ± 12.2 | 88.9 ± 14.4 | 0.0001 |
| Urinary ACR (mg/g) | 4.67 (2.39–8.71) | 9.57 (4.41–16.87) | <0.0001 |
| Use of anti diabetic drugs (n, %) | 208 (10.9) | 52 (26.3) | <0.0001 |
| Use of antihypertensive drugs (n, %) | 426 (22.4) | 63 (31.8) | 0.003 |

P values are calculated by t test for continuous variables and Chi-square test for categorical variables.

Data are means ± standard deviations or medians (interquartile ranges) for continuous variables, and numbers (proportions) for categorical variables.

*ACR* albumin-to-creatinine ratio, *BMI* body mass index, *DBP* diastolic blood pressure, *eGFR* estimated glomerular filtration rate, *FT3* free triiodothyronine, *FT4* free thyroxine, *FPG* fasting plasma glucose, *HDL-C* high-density lipoprotein cholesterol, *HbA1c* hemoglobin A1c, *LDL-c* low-density lipoprotein cholesterol, *SBP* systolic blood pressure, *TSH* thyroid-stimulating hormone, *TPOAb* thyroid peroxidase antibody, *TGAb* thyroglobulin antibody.
function over time, whereas hyperthyroidism conveyed a harmful effect [21]. In addition, other perspective studies also demonstrated that overt and subclinical hypothyroidism in older age (>85 years old) might even have a protective effect, particularly on span of life [28, 29]. However, our findings were conflicted with the results from the Kangbuk Samsung Health Study (KSHS), which was performed among 104,633 Korean participants with an average age of 38.0 years old and normal thyroid function at baseline. It reported that high-normal levels of TSH and low-normal FT3 levels below 3 pg/ml, but not FT4 levels, were associated with increased risk of incident CKD, defined as eGFR <60 mL/min/1.73 m² [20]. The disparate definitions of CKD might be a possible attributor for this discrepancy. In our study, we defined CKD not only on basis of eGFR but also on the presence of albuminuria. Albuminuria would be induced by high thyroid function and then could deteriorate renal function gradually [17, 30]. In addition, it might be due to the relatively older participants in our study than those in KSHS. With the increasing age, renal function declined [31] and thyroid function changed including increase of serum TSH and FT4, and decrease of total triiodothyronine [32].

In our study, we found that high levels of FT4, but not low levels of TSH, associated with incident CKD and rapid eGFR decline. Analogously, Ahmed MM reported that high levels of FT4, but not low levels of TSH, significantly associated with increasing severity of renal failure in patients with chronic renal failure and averagely aged 61 years old [33]. It might be partially due to the reduced sensitivity of pituitary with the increasing age; and then high FT4 levels could not generate negative feedback to TSH and suppress secretion of TSH [32, 34]. As shown in our study, serum FT4 was positively associated with age (β = 0.012, P = 0.0086), but TSH was not (β = −0.0021, P = 0.27).

However, the mechanisms of the positive associations of serum FT4 levels with incident CKD remain unclear. It might be due to the fact that high thyroid hormone levels increased the permeability of the glomerular barrier, and subsequently led to proteinuria [35]. Several studies have reported that overt proteinuria was observed in hyperthyroid rats, as well as in Graves’ disease patients [36]. It may also be possible

| Table 2 Association of thyroid hormone levels with incident CKD |
|---------------------------------------------------------------|
| Serum FT4                                                      |
| Tertile 1           | 47/699 (6.7) | 1.00 | 1.00 | 1.00 |
| Tertile 2           | 60/701 (8.6) | 1.28 (0.86–1.91) | 1.26 (0.83–1.91) | 1.24 (0.82–1.88) |
| Tertile 3           | 91/703 (12.9) | 1.97 (1.36–2.86) | 1.91 (1.30–2.81) | 1.88 (1.27–2.77) |
| P for trend         | <0.0001      | 0.0003 | 0.0008 | 0.001 |
| Each 1-pmol/l increase in FT4                                 | 198/2103 (9.4) | 1.13 (1.05–1.21) | 1.12 (1.04–1.20) | 1.12 (1.05–1.20) |
| Serum FT3                                                      |
| Tertile 1           | 65/687 (9.5) | 1.00 | 1.00 | 1.00 |
| Tertile 2           | 68/712 (9.6) | 1.07 (0.74–1.53) | 1.11 (0.76–1.62) | 1.12 (0.76–1.63) |
| Tertile 3           | 65/704 (9.2) | 1.09 (0.75–1.59) | 1.06 (0.72–1.57) | 1.04 (0.70–1.54) |
| P for trend         | 0.88         | 0.64 | 0.76 | 0.86 |
| Each 1-pmol/l increase in FT3                                 | 198/2103 (9.4) | 1.23 (1.01–1.49) | 1.21 (0.99–1.49) | 1.20 (0.98–1.47) |
| Serum TSH                                                      |
| Tertile 1           | 64/700 (9.1) | 1.00 | 1.00 | 1.00 |
| Tertile 2           | 74/700 (10.6) | 1.13 (0.79–1.61) | 1.31 (0.90–1.90) | 1.34 (0.92–1.94) |
| Tertile 3           | 60/703 (8.5) | 0.86 (0.59–1.26) | 0.99 (0.66–1.47) | 1.04 (0.69–1.56) |
| P for trend         | 0.70         | 0.45 | 0.99 | 0.80 |
| Each 1-μIU/ml increase in TSH                                  | 198/2103 (9.4) | 0.99 (0.91–1.07) | 0.99 (0.92–1.07) | 1.00 (0.94–1.07) |

Model 1: adjusted for age, sex, BMI at baseline
Model 2: further adjusted for triglyceride, HDL-c, diabetes and hypertension status, current smoking and drinking status, use of antihypertensive drugs, use of antidiabetic drugs, urinary ACR, eGFR at baseline
Model 3: further adjusted for TPOAb, TGAb at baseline
P for trend values for percentages of incident CKD are calculated by using Cochran–Mantel–Haenszel (CMH) method
Data are odds ratios (95% confidence intervals)
ACR albumin-to-creatinine ratio, BMI body mass index, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, FT3 free triiodothyronine, FT4 free thyroxine, HDL-c high-density lipoprotein cholesterol, TSH thyroid-stimulating hormone, TPOAb thyroid peroxidase antibody, TGAb thyroglobulin antibody.
that the presence of albuminuria could promote renal function deterioration. Previous studies found that the elevated ACR, even within normal range, was associated with a faster decline in eGFR [37, 38].

The major strength of our study is the prospective nature. We also carefully performed adjustments for the potential confounders, including the autoimmune thyroid antibodies. Besides, the CKD was defined based on either eGFR <60 ml/min/1.73 m² or presence of albuminuria recommended by the 2012 KDIGO clinical practice guideline. The rationales arise from the evidence that decrease eGFR or albuminuria were consistently associated with increased risk of death, end stage renal disease or cardiovascular mortality [39]. However, several limitations should be acknowledged. Firstly, the GFR was estimated by the 2009 CKD-EPI equation, rather than the gold standard of GFR measurement, a technetium 99m diethylene-triaminepentaacetic acid (99mTc-DTPA) renal dynamic imaging method. However, the accuracy of CKD-EPI equation to estimate GFR has already been confirmed and validated in many previous studies [40, 41]. Secondly, urinary albumin and creatinine were measured using a single spot urine sample. However, it

Table 3 Association of thyroid hormones with rapid eGFR decline during follow-up

| Serum FT4 | Case/number (%) | Model 1 | Model 2 | Model 3 |
|-----------|----------------|---------|---------|---------|
| Tertile 1 | 40/699 (5.7)   | 1.00    | 1.00    | 1.00    |
| Tertile 2 | 56/701 (8.0)   | 1.40 (0.92–2.14) | 1.38 (0.89–2.12) | 1.40 (0.91–2.16) |
| Tertile 3 | 69/703 (9.8)   | 1.72 (1.15–2.59) | 1.61 (1.06–2.45) | 1.64 (1.07–2.50) |
| P for trend | 0.004 | 0.009 | 0.03 | 0.02 |
| Each 1-pmol/l increase in FT4 | 165/2103 (7.9) | 1.12 (1.05–1.21) | 1.10 (1.02–1.18) | 1.10 (1.03–1.18) |

Table 4 Association of baseline FT4 with predicted risks for future outcomes of incident CKD

| Predicted risks for future outcomes of incident CKD | Case/number (%) | Model 1 | Model 2 | Model 3 |
|---------------------------------------------------|----------------|---------|---------|---------|
| Moderately increased risk | 177/2103 (8.4) | 1.12 (1.04–1.21) | 1.18 (1.05–1.34) | |
| Combined high and very high increased risk | 21/2103 (1.0) | 1.11 (1.03–1.19) | 1.22 (1.06–1.41) | |
| Each 1-pmol/l increase in FT4 | 1.33 (1.09–1.61) | 2.73 (1.41–5.27) | 2.61 (1.32–5.16) | |

Model 1: adjusted for age, sex, BMI at baseline
Model 2: further adjusted for triglyceride, HDL-c, diabetes and hypertension status, current smoking and drinking status, use of antihypertensive drugs, use of antidiabetic drugs, eGFR at baseline
Model 3: Further adjusted for TPOAb, TGAb at baseline

P for trend values for percentages of rapid eGFR decline are calculated by using Cochran–Mantel–Haenszel (CMH) method

Data are odds ratios (95% confidence intervals)

BMI body mass index, eGFR estimated glomerular filtration rate, FT3 free triiodothyronine, FT4 free thyroxine, HDL-c high-density lipoprotein cholesterol, TSH thyroid-stimulating hormone, TPOAb thyroid peroxidase antibody, TGAb thyroglobulin antibody

that the presence of albuminuria could promote renal function deterioration. Previous studies found that the elevated ACR, even within normal range, was associated with a faster decline in eGFR [37, 38].

The major strength of our study is the prospective nature. We also carefully performed adjustments for the potential confounders, including the autoimmune thyroid antibodies. Besides, the CKD was defined based on either eGFR <60 ml/min/1.73 m² or presence of albuminuria recommended by the 2012 KDIGO clinical practice guideline. The rationales arise from the evidence that decrease eGFR or albuminuria were consistently associated with increased risk of death, end stage renal disease or cardiovascular mortality [39]. However, several limitations should be acknowledged. Firstly, the GFR was estimated by the 2009 CKD-EPI equation, rather than the gold standard of GFR measurement, a technetium 99m diethylene-triaminepentaacetic acid (99mTc-DTPA) renal dynamic imaging method. However, the accuracy of CKD-EPI equation to estimate GFR has already been confirmed and validated in many previous studies [40, 41]. Secondly, urinary albumin and creatinine were measured using a single spot urine sample. However, it
was more practicable in large epidemiological studies [6], and was highly agree with the 24-h urinary albumin excretion [42, 43]. Thirdly, there were only two measurements of eGFR rather than repeated measurements of eGFR during follow-up. Fourthly, the current study was conducted in middle-aged and elderly Chinese adults. Hence, more cautions are needed to generalize the findings to other age and ethnic groups.

Conclusions
In conclusion, the present study indicated that a high level of serum FT4, rather than serum TSH and FT3, was associated with increased risk of incident CKD, rapid eGFR decline and increased risks of concurrent complications and further outcomes of CKD. Further studies aimed to validate our findings in other age and other ethnic groups, to examine the association of developing hyperthyroidism with incident CKD, and to explore related mechanisms are warranted in the future.

Abbreviations
ACR: albumin-to-creatinine ratio; BMI: body mass index; CV: coefficients of variation; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; FPG: fasting plasma glucose; FT3: free triiodothyronine; FT4: free thyroxine; HDL-c: high-density lipoprotein cholesterol; LDL-c: low-density lipoprotein cholesterol; OGTT: oral glucose tolerance test; OR: odds ratio; SD: standard deviation; TC: total cholesterol; TSH: thyroid-stimulating hormone; TPOAb: thyroid peroxidase antibody; TGB: thyroglobulin antibody.

Authors’ contributions
XH, MX, and GN contributed to the conception and design of this study. XH, LD, KP and LL were involved in the acquisition of data. XH and LD conducted the statistical analysis and interpretation of data, and drafted the manuscript. TW, ZZ, YL, CY, MX, WW, YN, and GN contributed to the revision of the manuscript for important intellectual content. All authors read and approved the final manuscript.

Author details
1 State Key Laboratory of Medical Genomics, Key Laboratory for Endocrine and Metabolic Diseases of Ministry of Health, National Clinical Research Center for Metabolic Diseases, Collaborative Innovation Center of Systems Biomedicine and Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai 200025, China. 2 Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai 200025, China.

Acknowledgements
We thank all the participants for their contribution and participation.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The underlying data in this manuscript arise from a dataset of National Clinical Research Center for Metabolic Diseases, and cannot be released, due to security considerations.

Ethics approval and consent to participate
The study was approved by the Institutional Review Board of Rui-Jin Hospital and in accordance to the Declaration of Helsinki. Written informed consent was obtained by each participant.

Funding
This work was supported by Grants 2013BAI09B13 from the National Clinical Research Center for Metabolic Diseases, 2015CB553600 from the 973 Program of China, 81471059, 81471062, 81321001 and 81390350 from the National Natural Science Foundation of China, 2015DFG05060 from the National International Science Cooperation Foundation, 2013ZDYB1002 from the Joint Research Program for Important Diseases of the Shanghai Municipal Commission of Health and Family Planning, and the Gaofeng Clinical Medicine Grant Support from the Shanghai Municipal Education Commission (2015ZS08).

Received: 14 August 2016 Accepted: 9 November 2016

References
1. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713–35.
2. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, et al. US renal data system 2010 annual data report. Am J Kidney Dis. 2011;57(1 Suppl 1):A8–e1–52.
3. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16(2):489–95.
4. Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA. 2012;308(22):2349–60.
5. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–47.
6. Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815–22.
7. Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379(9811):165–80.
8. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet. 2010;375(9722):1296–309.
9. Tohidi M, Hasheminia M, Mohrebi R, Khalili D, Hosseinpahan F, Yazdani B, et al. Incidence of chronic kidney disease and its risk factors, results of over 10 year follow up in an Iranian cohort. PLoS ONE. 2012;7(9):e45304.
10. den Hollander JG, Wulkan RW, Mantel MJ, Berghout A. Correlation between severity of thyroid dysfunction and renal function. Clin Endocrinol. 2005;62(4):423–7.
11. Katz AI, EmmanuelOU DS, Lindheimer MD. Thyroid hormone and the kidney. Nephron. 1975;15:223–9.
12. Villabona C, Sahnun M, Roca M, Mora J, Gomez N, Gomez JM, et al. Blood volumes and renal function in overt and subclinical primary hypothyroidism. Am J Med Sci. 1999;318(4):277–80.
13. Asvold BO, Bjoro T, Vatten LJ. Association of thyroid function with estimated glomerular filtration rate in a population-based study: the HUNT study. Eur J Endocrinol. 2011;164(1):101–5.
14. Gopinath B, Harris DC, Wall JR, Killey A, Mitchell P. Relationship between thyroid dysfunction and chronic kidney disease in community-dwelling older adults. Maturitas. 2013;75(2):159–64.
15. Kreisman SH, Hennessey JV. Consistent reversible elevations of serum creatinine levels in severe hypothyroidism. Arch Intern Med. 1999;159(1):79–82.
20. Zhang Y, Chang Y, Ryu S, Cho J, Lee WY, Rhee EJ, et al. Thyroid hormone levels and incident chronic kidney disease in euthyroid individuals: the Kangbuk Samsung Health Study. Int J Epidemiol. 2014;43(5):1624–32.
21. Meuwese CL, Gusselkoo J, de Craen AJ, Deker FW, den Ezen WP. Thyroid status and renal function in older persons in the general population. J Clin Endocrinol Metab. 2012;97(5):1554–62.
22. Vargas F, Moreno JM, Rodriguez-Gomez I, Wagensteen R, Osuna A, Alvarez-Guerra M, et al. Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol. 2006;154(2):197–212.
23. Moynihan R, Glasscock R, Doust J. Chronic kidney disease controversy: how expanding definitions are unnecessarily labelling many people as diseased. BMJ. 2013;347:f4298.
24. Stevens LA, Schmid CH, Greene T, Zhang YL, Coresh J, Manzi J, Landis R, et al. Comparative performance of the CKD epidemiology collaboration (CKD-EPI) and the modification of diet in renal disease (MDRD) study equations for estimating GFR levels above 60 ml/min/1.73 m^2. Am J Kidney Dis. 2010;56(3):486–95.
25. Bremner AP, Feddema P, Leedman PJ, Brown SJ, Belilby JP, Lim EM, et al. Age-related changes in thyroid function: a longitudinal study of a community-based cohort. J Clin Endocrinol Metab. 2012;97(5):1554–62.